Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call
Rhea-AI Summary
Neuronetics (NASDAQ: STIM) will release its third quarter 2025 financial and operating results before market open on Tuesday, November 4, 2025.
The company will host a live conference call and webcast to review results at 8:30 a.m. Eastern Time the same day. The webcast will be available in listen-only mode at https://edge.media-server.com/mmc/p/yxrs8osc. Telephone participation requires registration; joining 10 minutes early is recommended.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, STIM gained 5.49%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.9% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $10M to the company's valuation, bringing the market cap to $195M at that time.
Data tracked by StockTitan Argus on the day of publication.
MALVERN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that it plans to release third quarter 2025 financial and operating results prior to market open on Tuesday, November 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/yxrs8osc. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.6 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression.
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
When will Neuronetics (STIM) release its third quarter 2025 results?
What time is the Neuronetics (STIM) conference call for Q3 2025?
Where can I listen to the Neuronetics (STIM) Q3 2025 webcast?
How do I join the Neuronetics (STIM) conference call by phone on November 4, 2025?
Will Neuronetics (STIM) provide a replay of the Q3 2025 conference call?
